Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207811 · ClinicalTrials.gov registry record · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
A Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,280
- Enrollment target
- 20
- Study locations
NCT07207811 is a Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM) that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 1,280 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT07207811, a Phase 3 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,280 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
Conditions Studied
Interventions
- DRUG NNC6019-0001
- DRUG Placebo (NNC6019-0001)
Study Locations (20)
California
- University of California San Diego (UCSD) - Sulpizio Cardiovascular Center (SCVC) - La Jolla
- Keck School of Medicine USC - Healthcare Consultation Center 2 (HCCII) - Los Angeles
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute - Los Angeles
- UCI Medical Center - Orange
- Profound Research LLC at Southern California Heart Specialists - Pasadena
- University of California, San Francisco Medical Center - San Francisco
- Northbay Cardiology Inc. - Santa Rosa
- Lucile Packard Children's Hospital - Stanford
Illinois
- Northwestern University Clinical and Translational Sciences Institute - Chicago
- The University of Chicago Medicine - Chicago
- Endeavor Health - Glenbrook Hospital - Glenview
Arizona
- Mayo Clinic Hospital - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center - Washington D.C.
Florida
- UF Health Heart and Vascular Hospital - Gainesville
Georgia
- Northeast Georgia Heart Center, Pc (Nghc) - Gainesville
Hawaii
- The Queen's Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,280 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2029-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07207811
The ClinicalTrials.gov registry entry for NCT07207811 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 2 interventions - of which NNC6019-0001 is the first listed.
NCT07207811 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT07207811 about?
NCT07207811 is a clinical study titled "CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis". This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a tr...
What is the current status of trial NCT07207811?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,280 participants. The study started on 2025-10-02. Estimated completion is 2029-06-29.
What conditions does trial NCT07207811 study?
This clinical trial studies the following conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT07207811?
The interventions under investigation include: NNC6019-0001 (DRUG), Placebo (NNC6019-0001) (DRUG).
Who is sponsoring clinical trial NCT07207811?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207811 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.